This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

14 Jun 2012

Lilly Expands Partnership with Chinese Drugmaker Novast

Eli Lilly is increasing its investment in Chinese pharmaceutical company Novast Laboratories.

Eli Lilly and Co has announced plans to increase its links with Novast Laboratories, a Chinese company that focuses on generic and specialty pharmaceuticals.


Lilly originally invested in Novast several years ago but has now decided to increase its equity position by $20 million to maximise growth opportunities in the emerging market.


Over the next few years, Novast will establish a platform to support Lilly-branded generics, as well as increasing the manufacturing capacity at its headquarters in Nantong.


The company already has high-quality systems and manufacturing facilities in place, which cater for both the domestic Chinese and global markets.


Related News